^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    AR-V7 degrader

    Related drugs:
    2d
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=138, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    9d
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    15d
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=134, Active, not recruiting, Novartis Pharmaceuticals
    Trial initiation date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    22d
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    2ms
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    2ms
    CJSB462B12201: A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) (2024-520155-24-00)
    P1/2, N=46, Recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    2ms
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    3ms
    A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    luxdegalutamide (ARV-766)
    7ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    7ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    7ms
    A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    luxdegalutamide (ARV-766)
    3years
    HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer (AACR 2023)
    The androgen deprivation therapy (ADT) alone and its combination with hormone therapy that block AR signaling (e.g., enzalutamide or abiraterone) are effective treatments for advanced prostate cancer. No animal was found dead or moribund and no test article-related changes in clinical signs,body weights, food consumption, ophthalmologic examinations, clinical pathology parameters, sperm analysis, urinalysis, organ weights, histopathology. In conclusion, HSK38008 is a promising oral AR-V7 degrader with better efficacy than enzalutamide and ARV-110 in AR and AR-V7 positive, and potential AR mutants mCRPC.
    Late-breaking abstract • Metastases
    |
    AR (Androgen receptor)
    |
    AR mutation • AR T878A • AR splice variant 7 • AR-V7 positive • AR H875Y • AR T878S
    |
    Xtandi (enzalutamide) • abiraterone acetate • bavdegalutamide (ARV-110) • HSK38008